Acting CEO Frans Wuite will tell you more about Herantis Pharma's operations in today's BioStock Investor Pitch at 10:00.
Se Herantis Pharma acting CEO Frans Wuite present the company below.
BioStock Investor Pitch: Herantis Pharma
Finnish Herantis Pharma, listed in both Finland and Sweden, is developing its lead candidate HER-096 for Parkinson's disease. HER-096 is to take the final preclinical steps before initiating Phase I studies and the company is currently in the process of a rights issue.